A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas



Status:Completed
Conditions:Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:Any - 1
Updated:5/5/2014
Start Date:September 2009
End Date:May 2011
Contact:Alexandra C Sowa, BA, MA
Email:Alexandra.Sowa@yale.edu
Phone:443-386-3808

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Infantile Hemangioma Tumor Size and C/T Polymorphism Within CTCF Binding Site Six

The purpose of this study is to evaluate the genotype of CTCF, a proven transcription
factor, in patients with infantile hemangiomas and to monitor tumor growth. The
investigators aim to determine whether or not the CTCF genotype might serve as an early and
reliable predictor of tumor growth.

This study seeks to examine a potential relationship between CTCF genotype and hemangioma
size and growth rate. In addition to the initial visit, patients will return to our clinic
for evaluation at two weeks, one month, two months, six months, and one year. At each
visit, patients' hemangiomas will be measured and photographed. At one point over the
course of evaluation, a blood sample will be taken from each patient for evaluation of C/T
polymorphism at CTCF binding site six.

Inclusion Criteria:

- Hemangioma must appear within one month prior to enrollment

Exclusion Criteria:

- Hemangioma appeared before one month prior to enrollment
We found this trial at
1
site
Yale Dermatology Associates
New Haven, Connecticut 06519
?
mi
from
New Haven, CT
Click here to add this to my saved trials